MedPath

Adaptation, feasibility, and investigation of CALM on cognitive and psychological problems of patients with advanced cancer

Phase 2
Recruiting
Conditions
Malignant solid tumor as follows: stage III B or IV lung cancer
any stage of pancreatic cancer, stage III or IV ovarian and fallopian tube cancers, or other stage IV gynecological cancer
and stage IV breast, genitourinary, gastrointestinal, melanoma, sarcoma, or endocrine cancers.
Malignant neoplasms, of specified sites, except of lymphoid, haematopoietic and related tissue
C00-C80
Registration Number
IRCT20230627058602N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Fluency in Persian language
Diploma or higher level of education and living in Tehran
Diagnosis of the metastatic solid tumor as follows: stage III B or IV lung cancer; any stage of pancreatic cancer, stage III or IV ovarian and fallopian tube cancers, or stage IV of other gynecological cancers; and stage IV breast, genitourinary, gastrointestinal, melanoma, sarcoma, or endocrine cancers
Life expectancy 12 to 18 months
A score greater than or equal10 on the Patient Health Questionnaire (PHQ9)
A score greater than 5 on the Post-traumatic Stress Disorder Checklist (PCL-5)
A score greater than or equal to 20 on the Death and Dying Distress Scale (DADDS)
A score lesser than 27 on Mini-Mental State Examination (MMSE)

Exclusion Criteria

Language or communication barriers hindering psychotherapy
Consciousness problems or inability to participate in assessment and intervention sessions
Disorder and features of acute psychosis
Suicidal thoughts and attempts
Severe sensorimotor disabilities
Brain damage or any medical condition that better explains the cognitive and psychological problems of patients with advanced cancer
Concomitant psychotherapy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath